Local Anesthesia Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

The global local anesthesia drugs market was valued at USD 2.75 billion in 2023, growing at a CAGR of 4.36% during the forecast period from 2024 to 2030 to reach USD 3.54 billion by 2030. The demand for local anesthesia drugs is primarily being boosted by the increasing figures of various surgical procedures owing to the increasing prevalence of chronic diseases, worldwide. In addition, the introduction of new and effective drugs such as articaine, levobupivacaine, and ropivacaine, advancements in drug delivery technologies, the expanded use of local anesthetics in postoperative pain, the increasing drugs launches and approval among others are thereby contributing to the overall growth of the local anesthesia drugs market during the forecast period from 2024-2030.

Local Anesthesia Drugs Market Dynamics:

The local anesthesia drugs market is witnessing a growth in product demand owing to various factors, one of the key factors being the increasing number of surgical procedures across the globe. As per the World Health Organization (WHO) 2021 data, nearly 2,50,129 inpatient surgical procedures were performed in Georgia in 2021. Also, the source stated that approximately 85,29,608 inpatient surgical procedures were performed in Russian Federation in 2021.

The Organization for Economic Co-operation and Development (OECD) 2023, nearly 82,380 cesarean section surgical procedures were performed in Spain in 2020. Further, as per the same source, nearly 18,805 tonsillectomy procedures were done in Canada in 2020.

The above statistics indicate that the number of surgical procedures is increasing across the globe. Local anesthesia is widely used in such procedures as it numbs a small area of the body to reduce pain and ease surgical procedures. Thus, the growth in the number of such surgeries will propel the demand for local anesthesia drugs in the market.

The growth of the market for local anesthesia drugs is also fueled by the introduction of new and effective drugs such as articaine, levobupivacaine, and ropivacaine. This growth is supplemented by increasing healthcare expenditure in developing countries such as India, China, and Brazil, where the number of surgeries performed has been on a steady rise.

Furthermore, the development and approvals of novel local anesthesia drugs are proving to be a new revenue-generating resource for market players. For instance, in February 2021, PainPass launched the first Cannabidiol (CBD)/lidocaine product line targeting those with chronic pain and for numbing muscles externally.

Also, in May 2021, Heron Therapeutics, Inc. got approval from the US Food and Drug Administration (FDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution. ZYNRELEF is the first and only extended-release dual-acting local anesthetic (DALA) that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam. Therefore, the above-mentioned factors are contributing to the growth of the local anesthesia drugs market during the forecast period from 2024-2030.

However, side effects related to drugs, stringent regulatory framework, and others may restrict the local anesthesia drugs market growth.

The local anesthesia drugs market was significantly impacted during the period of COVID-19 pandemic. During the initial stage of the pandemic, the sale of local anesthesia drugs suffered a collapse owing to the imposition of strict lockdown rules, and disruption in manufacturing, and supply. Moreover, the outbreak of the pandemic led to the cancellation of outpatient visits and the suspension of non-emergency hospitalization and surgical procedures for various ailments such as orthopedic, gynecological, urological, cosmetic, cardiovascular, dental, and others. However, the vaccine development of COVID-19 initiated the process of economic recovery. Also, the easing of lockdown restrictions and the return of normalcy in the economic landscape initiated the process of resumption of regular healthcare services such as outpatients visits for various treatments, therapies, and surgeries for the aforementioned ailments, thereby bringing the demand for products on track in the local anesthesia drugs market.

Local Anesthesia Drugs Market Segment Analysis:

Local anesthesia drugs market by Drug Type (Bupivacaine, Lidocaine, Benzocaine, Prilocaine, Chloroprocaine, and Others), Mode of Administration (Surface Anesthetic and Injectable), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the drug type segment of the local anesthesia drugs market, the Bupivacaine category is expected to amass a significant revenue share in the year 2023. This can be ascribed to the advantages and applications associated with PRP systems.

Bupivacaine is a strong substance that can cause prolonged anesthesia. It is a common medication for providing prolonged analgesia during labor or during the postoperative period due to its long duration of action and propensity to provide more sensory than the motor block. Bupivacaine has a slower onset of action (about 5-10 minutes after injection) but its effects last much longer, for about 4-8 hours.

It is commonly used to produce infiltration and conduction anesthesia. Bupivacaine injection is used as an anesthetic for local and regional anesthesia for several procedures, such as surgery and diagnostic, therapeutic, and obstetrical procedures. Bupivacaine is the standard drug that is used to produce extradural lumbar and thoracic blockade and to produce spinal subarachnoid anesthesia.

Additionally, several market members are putting strategic plans into action, which can help the market to expand. For instance, in March 2021, Pacira BioSciences Inc. announced that the US FDA has approved the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL label to include use in patients 6 years of age and older for single-dose infiltration to produce postsurgical local analgesia.

Therefore, the advantages offered by Bupivacaine are predicted to contribute to the increasing demand for this drug type thereby driving the growth of the overall local anesthesia drugs market during the forecast period.

North America is expected to dominate the overall Local Anesthesia Drugs Market:

Among all the regions, North America is estimated to account for the largest share of the global local anesthesia drugs market in the year 2023. Owing to the factors such as the increasing number of surgeries, the rising aging population suffering from chronic conditions, the growing use of local anesthetics in postoperative pain, and advancements in anesthesia administration, are expected to aid in the growth of the North America local anesthesia drugs market. Furthermore, high disposable income, sophisticated healthcare infrastructure, and regulatory approval for new drugs, also helped the market growth in this region.

For instance, the International Society of Aesthetic Plastic Surgery 2021 report stated that 7,347,900 total procedures including 1,992,296 surgical procedures and 5,355,604 non-surgical procedures were performed in the US in 2021. These statistics indicate that surgical procedures are constantly increasing in the region, ultimately driving the demand for local anesthesia drugs. As per the same source, nearly 672,683 surgical procedures were performed in Mexico in 2021, including 102,760 liposuction procedures.

Coupled with the factors mentioned above, strategic activities such as product launches and approvals, mergers, acquisitions, partnerships, and others also help in boosting regional product demand. For instance, in December 2021, Hikma Pharmaceuticals PLC launched Bupivacaine HCl Injection USP through its US affiliate Hikma Pharmaceuticals USA Inc. The company launched 0.25%, 0.5%, and 0.75% in 10 milliliters and 30-milliliter doses. Thus, such strategic steps help to increase the demand for local anesthesia drugs, thereby driving the North America local anesthesia drugs market forward during the forecast period.

Local Anesthesia Drugs Market Key Players:

Some of the key market players operating in the local anesthesia drugs market include Fresenius Kabi USA, Pacira BioSciences, Inc., Pfizer, Septodont Holding, Baxter, Laboratoires Théa SAS, Luye Pharma Group, PAINPASS, GLENMARK PHARMACEUTICALS LTD., Aspen Group, Endo International plc, Hikma Pharmaceuticals PLC, Nichi-Iko Pharmaceutical Co., Heron Therapeutics, Inc., Teva Pharmaceutical Industries Ltd, and others.

Recent Developmental Activities in the Local Anesthesia Drugs Market:

• In March 2021, Luye Pharma Group received approval for clinical trials by the Centre for Drug Evaluation of China’s National Medical Products Administration for its LY09606, the first Ropivacaine multivesicular liposome formulation local anesthetic to be used as a postoperative analgesic.
• In August 2020, B.Braun Melsulgen AG and Royal Philips announced that Onvision needle tip tracking technology for regional anesthesia got the 510(k) clearance from the US FDA.

Key Takeaways from the Local Anesthesia Drugs Market Report Study

• Market size analysis for current local anesthesia drugs market size (2023), and market forecast for 6 years (2024-2030)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global local anesthesia drugs market.
• Various opportunities available for the other competitor in the local anesthesia drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current local anesthesia drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for local anesthesia drugs market growth in the coming future?

Target Audience who can be benefited from this Local Anesthesia Drugs Market Report Study

• Local anesthesia drugs products providers
• Research organizations and consulting companies
• Local Anesthesia Drugs-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in local anesthesia drugs
• Various End-users who want to know more about the local anesthesia drugs market and the latest technological developments in the local anesthesia drugs market.

Frequently Asked Questions for the Local Anesthesia Drugs Market:

1. What are local anesthesia drugs?

Local anesthesia, also called local anesthetic, is usually a one-time injection of medicine that numbs a small area of the body. They produce anesthesia by inhibiting the excitation of nerve endings or by blocking conduction in peripheral nerves.

2. What is the market for global local anesthesia drugs?

The global local anesthesia drugs market was valued at USD 2.75 billion in 2023, growing at a CAGR of 4.36% during the forecast period from 2024 to 2030 to reach USD 3.54 billion by 2030.

3. What are the drivers for the global local anesthesia drugs market?

The demand for local anesthesia drugs is primarily being heightened by the increasing number of surgical procedures including cosmetic procedures, dental procedures, cardiovascular, and others owing to the increasing prevalence of chronic diseases. In addition, the growing use of local anesthetics in postoperative pain, and increasing drug launches and approvals, among others, thereby contribute to the overall growth of the local anesthesia drugs market during the forecast period from 2024-2030.

4. Who are the key players operating in the global local anesthesia drugs market?

Some of the key market players operating in the local anesthesia drugs market include Fresenius Kabi USA, Pacira BioSciences, Inc., Pfizer, Septodont Holding, Baxter, Laboratoires Théa SAS, Luye Pharma Group, PAINPASS, GLENMARK PHARMACEUTICALS LTD., Aspen Group, Endo International plc, Hikma Pharmaceuticals PLC, Nichi-Iko Pharmaceutical Co., Heron Therapeutics, Inc., Teva Pharmaceutical Industries Ltd, and others.

5. Which region has the highest share in the local anesthesia drugs market?

North America is expected to dominate the overall local anesthesia drugs market during the forecast period from 2024-2030. Factors such as the upsurge in the aging population susceptible to various disorders, rise in the number of various surgeries, surging population base suffering from chronic diseases, and presence of key players in the region, among others, will positively impact the North American local anesthesia drugs market. Furthermore, high disposable income, sophisticated healthcare infrastructure, regulatory approval for new devices, and high awareness about anesthesia drugs also helped the market growth in this region.


This product will be delivered within 2 business days.